For a moment, imagine the daily noise of diabetes going quiet. No alarms. No finger sticks. No mental arithmetic every time you eat. That “what if?” has hovered over type 1 diabetes for a century—then, in August 2025, a startling first: a man with long-standing T1D began producing his own insulin after receiving gene-edited islet cells—and he did it without lifelong immunosuppressant drugs.

This isn’t hype from a mouse lab. It’s a peer-reviewed clinical case in the New England Journal of Medicine (NEJM). Researchers in Sweden and the U.S. used CRISPR edits to make donor islet cells “invisible enough” to the immune system—dialing down rejection signals and boosting a “don’t eat me” marker (CD47). Twelve weeks after the transplant, the patient’s body left those edited cells alone, and they secreted insulin. He still uses insulin therapy for now, but the signal is clear: a functional cure path may finally be opening. Live Science+2New England Journal of Medicine+2

That single case reframes the race. It validates a core idea many teams have bet on: if we can either hide therapeutic beta cells from immune attack (gene editing) or shield them (encapsulation devices), we might restore natural insulin production at scale. Below, we map the players turning this proof-of-concept into a product—and the market reality behind them.

Why This Case Matters (and what it actually shows)

• The immunosuppression problem: Traditional islet transplants can work, but patients usually need powerful immunosuppressants for life—trading glucose swings for infection risk. The NEJM case demonstrated genetically engineered, allogeneic islet cells functioning without triggering rejection in the first weeks—no chronic immunosuppression required. Live Science
• How they hid the cells: Multiple CRISPR edits reduced cell-surface “ID badges” that flag foreign tissue and increased CD47, a protein that effectively says “don’t attack me.” It’s immune camouflage, not full invisibility—and it worked long enough to produce insulin. Live Science
• What it doesn’t prove (yet): Durability beyond the early window, scale-up, dosing to insulin independence, and reproducibility across diverse patients remain to be shown. The authors explicitly call for follow-up trials. Live Science

The Four Companies to Watch

1) Vertex Pharmaceuticals (NASDAQ: VRTX): The Benchmark Builder

If there’s a “program of record” in diabetes cell therapy, it’s Vertex. Born from the Semma Therapeutics acquisition and bolstered by the later buyout of ViaCyte, Vertex now controls both the cell source (stem-cell–derived islets) and two delivery approaches:

• VX-880: Infusion of stem-cell–derived islets with standard immunosuppression showed compelling early signals (reduced insulin needs, improved glucose control).
• VX-264: Puts those same cells into a device designed to shield them from the immune system—aiming to remove immunosuppression entirely. Vertex completed Part A & B enrollment and day-90 analyses earlier this year and updated the T1D portfolio in March 2025. Vertex+1

Why Rabbt likes them: Vertex is the rare biotech with massive CF cash flow to fund hard problems, clinical discipline, and device-plus-cells integration—critical for real-world use. If any large-cap can industrialize islet replacement at scale, it’s Vertex.

Market snapshot (current): VRTX closed around $383.12 (Sept 19, 2025, U.S. market), with market cap near $98–101B across trackers. Macrotrends

2) Sana Biotechnology (NASDAQ: SANA): Hypoimmune Cells Cross the Rubicon

Sana’s core bet is hypoimmune (HIP) cells—engineered so the body tolerates them without chronic immunosuppression. The NEJM paper’s findings align with this immune-evasion thesis, and Sana highlighted the publication as evidence that engineered islet cells can evade immune destruction in humans. That’s the crux: not just working cells, but cells the immune system ignores. Sana

Why Rabbt likes them: The first human proof that immune-evasive edits work is a step change. If Sana can translate this into durable, scalable doses that drive insulin independence, it could leapfrog device-only strategies. The risk: manufacturing complexity and regulatory scrutiny on edited allogeneic tissues.

Market snapshot (current): SANA trades around $3.09 (Sept 19, 2025). Early-stage, but the scientific catalyst is real.

3) Eli Lilly (NYSE: LLY): The Big-Pharma “Every Angle” Strategy

Lilly owns the GLP-1 era, but it’s also quietly built a presence in encapsulated islet therapies—first via partnership, then by acquiring Sigilon (2023). Add in scale manufacturing moves (a new $5B U.S. plant announced Sept 16, 2025) and you have a company positioning to produce both metabolic drugs and cell-based cures at global scale. Breakthrough T1D+2Reuters+2

Why Rabbt likes them: Two words—distribution and durability. If a cell therapy hits, Lilly has the factories, payer relationships, and diabetes franchise to deploy it. And while cell therapies mature, Lilly’s cash engine (obesity/diabetes meds) keeps the lights blazing.

Market snapshot (current): LLY trades around $751.99; market-cap trackers put it roughly $675–712B in mid-September 2025. Macrotrends+1

4) Novo Nordisk (NYSE: NVO): Devices Today, Hypoimmune Tomorrow

Novo Nordisk is best known for GLP-1s, but it’s also investing in cell therapy paths (e.g., partnerships like Aspect Biosystems) while pressing forward on oral anti-obesity programs that move the needle on metabolic disease. Shares jumped on positive oral pill data this week, underscoring how Novo can finance moonshots like beta-cell replacement while dominating today’s market. Breakthrough T1D+1

Why Rabbt likes them: Novo + devices + partnerships could create a two-track future: drugs to reduce insulin demand and cells to restore supply. If encapsulation or immune-evasion nails durability, Novo’s go-to-market machine follows.

Market snapshot (current): NVO trades around $61.40; market-cap trackers sit near $271–276B as of Sept 19, 2025. Macrotrends+1

Dark Horses Worth Knowing

• Sernova (TSX: SVA / OTC: SEOVF): The Cell Pouch™ is a surgically implanted, vascularized “home” for islets, aiming to improve engraftment and access to oxygen/nutrients. Recent interim Phase 1/2 updates remained positive; iPSC-islet trials with partner Evotec are anticipated around 2026 after Cohort C. Bonus: a recent collaboration with Eledon on immune modulation. PMC+2GlobeNewswire+2
• eGenesis (private): Pushing xenotransplantation (pig islets/organs) with CRISPR gene edits to avoid viral risks and immune rejection; broader momentum in pig-to-human kidney transplants could spill into islets. The Wall Street Journal+1

What Changes If This Works?

• The math of management flips: Continuous glucose monitors, pumps, and GLP-1s shrink in centrality if a one-time or infrequent cell dose restores physiologic insulin.
• Manufacturing becomes medicine: Whoever scales a consistent, edited islet line with long-term durability wins. That favors teams with industrial know-how (Vertex’s device integration; Lilly/Novo’s factories; Sana’s allogeneic cell engineering).
• Regulatory playbook evolves: FDA and EMA will need standards for durability endpoints, immune-evasion edits, and retrievability (especially devices). That means longer, larger trials—and clear, patient-centric claims.

The Top Three Companies Performing in the Market (Right Now)

(As of market close around September 19, 2025; values rounded; sources cited)

1. Eli Lilly (LLY)
   • Share price: ~$751.99
   • Market cap: ~$675–712B (multiple trackers)
   • Why it’s hot: Unrivaled GLP-1 cash flows fund advanced manufacturing and cell-therapy bets (via Sigilon acquisition), plus ongoing obesity pipeline catalysts. Macrotrends+1
2. Novo Nordisk (NVO)
   • Share price: ~$61.40
   • Market cap: ~$271–276B
   • Why it’s hot: Positive oral GLP-1 readouts this week reignited momentum; metabolic dominance provides runway to back device/cell-therapy combos. Macrotrends+1
3. Vertex (VRTX)
   • Share price: ~$383.12
   • Market cap: ~$98–101B
   • Why it’s hot: The most integrated T1D cell-therapy program (cells + device), disciplined clinical execution, and cash from CF to keep pressing. Macrotrends

What to Watch Next (Catalyst Checklist)

• Durability data from immune-evasive islet trials (months → years).
• Insulin-independence rates and time-to-independence in edited or encapsulated cohorts.
• Device refinements (oxygenation, retrievability, fibrosis control) for encapsulation platforms.
• Manufacturing scale-up: lot-to-lot consistency, cost per dose, cold chain, and quality metrics.
• Regulatory pathfinders: initial BTD/PRIME-like designations, endpoints, and real-world evidence plans.

The Bottom Line

Sometimes a field shifts with one small, undeniable human moment. A single patient, a dozen weeks, a whisper of insulin where there was none. It’s not victory yet—but it’s the first footprint on a new path. From here, it’s about durability, manufacturing, and access. The winners won’t just be the companies shipping cell doses; it’ll be the people who, for the first time in years, can eat a meal without fear. That’s a future worth investing in—scientifically and financially.

Sources & References

• Clinical breakthrough: Live Science coverage of the NEJM case (Aug 13, 2025), including the CRISPR-based immune-evasion details and early insulin production in the patient. Live Science
• Primary paper: NEJM — “Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression” (2025). New England Journal of Medicine+1
• Vertex T1D pipeline (VX-880, VX-264; device + cells): Company pipeline page and March 28, 2025 program update. Vertex+1
• Sana Biotechnology hypoimmune cells: Company IR press note highlighting the NEJM publication’s significance for immune-evasive islets. Sana
• Lilly moves in cell therapy & manufacturing: Breakthrough T1D overview (Sigilon acquisition); major U.S. plant announcement (Sept 16, 2025). Breakthrough T1D+2Reuters+2
• Novo Nordisk newsflow: Positive oral GLP-1 data and market reaction (Sept 18, 2025). The Guardian
• Sernova Cell Pouch & timelines: Peer-review and company updates incl. Evotec partnership and Eledon collaboration. PMC+2GlobeNewswire+2
• Context on xenotransplant momentum: eGenesis organ programs, recent capital and clinical milestones. The Wall Street Journal+1
• Market metrics (captured at/near Sept 19, 2025): Real-time quotes and market-cap trackers for LLY, NVO, VRTX, SANA, CRSP. StockAnalysis+3Macrotrends+3Macrotrends+3

Heads-up for readers: Share prices move; we timestamp numbers and cite sources so the post stays transparent and current to publication day.